Ablation And Mapping Catheter Articles & Analysis
28 news found
Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR), the global leader in real-time iCMR cardiac ablation products, is pleased to announce that the Company has submitted for approval to commence a real-time iCMR-guided ventricular tachycardia (VT) ablation clinical trial. The name of the study is “Vision-MR Ablation of VT” or VISABL-VT. VISABL-VT is a prospective, ...
ByImricor
Adagio Medical, Inc., a leading innovator in catheter ablation technologies for atrial fibrillation (AF) and ventricular tachycardia (VT), announced the publication of the results of its Cryocure-2 ultra-low temperature cryoablation (ULTC) study in patients with AF in the Journal of American College of Cardiology (JACC), Clinical Electrophysiology.1 The study prospectively enrolled 79 patients at ...
The AcQForce Flutter trial was designed to evaluate the safety and efficacy of the AcQBlate FORCE sensing ablation catheter and system in the treatment of right atrial typical flutter. ...
announces a successful first-in-BC investigational* clinical procedure using the Globe® Mapping and Ablation System. Dr. Marc Deyell of St. Paul’s Hospital leads the study using the Globe System to navigate inside the heart and diagnose where the rhythm disturbances occur. ...
Adagio Medical, Inc., a leading innovator in catheter ablation technologies for atrial fibrillation (AF) and ventricular tachycardia (VT), today announced first-in-human cases of pulsed field cryoablation (PFCA) for the treatment of atrial fibrillation (AF). The cases were performed at Medicover Hospital, Warsaw, Poland by Dr. Pawel Derejko, Head of the Department of Cardiology at Medicover and ...
” “The Globe PF System is unique in that it combines mapping and ablation into a single catheter,” said Dr. Koruth. “We could navigate the Globe Catheter to the pulmonary veins, confirm contact with the tissue, and be confident that the therapy would be delivered where needed. After ...
The inception of this study highlights Acutus’ unique therapeutic position offering the first and only force sensing gold-tip ablation catheter, AcQBlate Force, designed to deliver either radiofrequency (RF) or PFA therapy – with the added benefit of fully integrating with therapy guidance provided by the novel AcQMap 3D Imaging and ...
Adagio Medical, Inc., a leading innovator in catheter ablation technologies for atrial fibrillation (AF) and ventricular tachycardia (VT), announced the results of its CryoCure-2 ultra-low temperature cryoablation (ULTC) prospective multi-center study in patients with AF at the 2021 Heart Rhythm Society Annual Meeting. The late-breaking clinical trials presentation was delivered by Dr. Tom De ...
The technology targets arrhythmias by delivering quick bursts of high-voltage, high-frequency PEF energy to ablate the heart. Two innovations are unique to the CENTAURI PEF system: The proprietary WAVE1 waveform which may reduce muscle stimulation and eliminate gas emboli, a potential source for strokes, observed with other ablation products. The proprietary ...
Adagio Medical, Inc., a leading innovator in catheter ablation technologies for atrial fibrillation (AF) and ventricular tachycardia (VT), today announced successful first-in-human use of ultra-low temperature cryoablation (ULTC) for the treatment of monomorphic VT. The two-hour mapping and ablation procedure was performed by ...
Superiority trial showed a 29% difference in effectiveness at 12 months and a 35% difference in effectiveness at 18 months for long-standing persistent Afib patients. Study also showed improved Electrophysiology Lab efficiency AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced U.S. Food and ...
PEF targets arrhythmias by delivering quick bursts of high-voltage, high-frequency energy to ablate the heart. Two major innovations are unique to the CENTAURI system: The proprietary WAVE1 waveform reduces muscle stimulation and eliminates microbubbles seen with other PEF ablation products that can cause strokes. The proprietary CENTAURI Connect module ...
In the recently published RedHeart Study the Coala Heart Monitor was used to remotely monitor 821 women with palpitation issues for 60 days. Over 200,000 individual ECG strips were analyzed. The direct ECG response of the Coala Heart Monitor contributed to reduced levels of anxiety, depression and symptoms of palpitations. The direct ECG response of the Coala also led to an increased quality of ...
SAN CARLOS, California, April 6, 2021 — Galaxy Medical (Galaxy) and Japan Lifeline (JLL) today announced an exclusive distribution agreement for the ALPHA1 ablation catheter in the United States, developed by Japan Lifeline for use with the Galaxy CENTAURI™ Pulsed Electric Field (PEF) System. ...
The funds are being used to advance the development of Galaxy’s flagship product CENTAURI™, which uses Pulsed Electric Field (PEF) technology to treat cardiac arrhythmias. “Pulsed electric field ablation is a game-changing intervention in cardiac arrhythmias, and the Galaxy CENTAURI system has distinct advantages that should make it a best-in-class entry in ...
FARAPULSE Inc. today announced the first patients were treated in the ADVENT Trial, a U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) pivotal trial to evaluate the safety and effectiveness of its Pulsed Field Ablation (PFA) system for the treatment of paroxysmal Atrial Fibrillation (AF). AF is a heart rhythm disorder that affects nearly 6 million Americans and makes ...
Volta Medical, a pioneering French-based HealthTech startup, working on novel artificial intelligence (AI) algorithms to treat cardiac arrythmias, today announced that it has successfully raised 23 million Euros. The financing round was led by Gilde Healthcare with participation of existing shareholder Pasteur Mutualité. The new capital will allow the company to establish its revolutionary ...
Adagio Medical, Inc., a leading innovator for the treatment of atrial fibrillation (AF) and ventricular tachycardia (VT), and developer of the intelligent Continuous Lesion Ablation System (iCLAS), today announced that it has closed a $42.5 million Series E equity financing. Proceeds from the financing will be used to support the ongoing iCLAS Investigational Device Exemption (IDE) trial, ...
It is a powerful 122-electrode mapping and ablation system that combines best-in-class technologies into a single catheter, uniting the rapid pulmonary vein isolation (PVI) of balloon catheters, the flexibility of single-tip catheters, and the high-definition mapping of multi-electrode ...
Key features of the CENTAURI System include: Plug and play with all cardiac mapping and navigation systems Compatible with all market released contact force catheters Programable dosing to address variable tissue thickness Proprietary wave control algorithm for complete elimination of micro-bubbles during PEF delivery Automatic impedance monitoring Ante ...